Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US15506380Application Date: 2015-08-25
-
Publication No.: US10081624B2Publication Date: 2018-09-25
- Inventor: Akira Kaieda , Naoki Ishii , Hiroshi Nara , Masato Yoshikawa , Masaki Daini , Masashi Toyofuku , Kousuke Hidaka
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Foley & Lardner LLP
- Priority: JP2014-172058 20140826
- International Application: PCT/JP2015/073858 WO 20150825
- International Announcement: WO2016/031815 WO 20160303
- Main IPC: C07D413/12
- IPC: C07D413/12 ; C07D413/14 ; C07D417/14 ; C07D471/04 ; C07D487/04 ; C07D491/08 ; C07D513/04

Abstract:
The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
Public/Granted literature
- US20180222896A1 HETEROCYCLIC COMPOUND Public/Granted day:2018-08-09
Information query